A314130 Share Price Performance
₩6,710.00
3805.00 (130.98%)
Price ₩6,710.00
Share Pricen/a
Genome & Company's (KOSDAQ:314130) Shares Leap 30% Yet They're Still Not Telling The Full Story
Nov 27
Genome & Company Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A314130 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Genome & Company Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -802.84
- 55.87%
- -107.18%
- 25.1%
About A314130
- Founded
- 2015
- Employees
- 98
- CEO
- WebsiteView website
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements. In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is based in Seongnam-si, South Korea.
